Related Experiment Video
Updated: Oct 23, 2025
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Effect of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on COVID-19 outcome: A Record Based
Arnab Bhattacharyya1, Susovan Halder2, Tanuka Mandal3
1Sr. Consultant in Dept. of Medicine-North 24 Pgs. District Hospital, Barasat, West Bengal;Corresponding Author.
Insights
Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) showed a trend towards less severe COVID-19 outcomes. These important cardiovascular drugs should be continued in patients with COVID-19 infection.
Area of Science:
- Cardiology
- Infectious Diseases
- Pharmacology
Background:
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes COVID-19, a global pandemic.
- SARS-CoV-2 utilizes the ACE-2 receptor for host cell entry, influencing research into ACEI/ARB therapies.
- The interplay between ACEI/ARB and COVID-19 severity remains an area of significant clinical interest.
Purpose of the Study:
- To investigate the association between Angiotensin-converting enzyme inhibitors (ACEI)/Angiotensin receptor blockers (ARB) use and COVID-19 disease severity.
- To evaluate the impact of ACEI/ARB on patient outcomes in a real-world clinical setting.
Main Methods:
- An observational, record-based study was conducted using data from fourteen physicians in West Bengal.
- The study analyzed associations between ACEI/ARB use and COVID-19 severity.
- Ethical approval was obtained from the Calcutta School of Tropical Medicine Clinical Research Ethics Committee.
Main Results:
- Increasing age, male sex, and comorbidities like Diabetes and COPD were significantly associated with moderate to severe COVID-19.
- ACEI/ARB use showed a trend towards association with less severe COVID-19.
- This association did not reach statistical significance in the current study.
Conclusions:
- ACEI/ARB medications should be continued in patients diagnosed with COVID-19 who are already prescribed these drugs.
- The findings support the ongoing use of ACEI/ARB in patients with both cardiovascular conditions and COVID-19.
Background:
Since its first identification in December 2019, in WUHAN (CHINA), SARS-COV-2, causative agent of Corona virus pandemic, has affected millions of people worldwide, causing thousands of death. There is much speculation about the interplay between ACEI/ARB and Corona virus infection, as for internalization into host cell SARS-COV-2 binds through S spike protein to ACE-2, aided TMPRSS2.
Methods:
A record based observational study has been conducted (data obtained from the clinics of fourteen physicians) in two worst affected districts of West Bengal, to find out the association of ACEI/ARB on patients, suffering from Corona virus infection. The study-protocol has already been approved by Clinical Research Ethics Committee of Calcutta School of Tropical Medicine. (IEC Ref. No: CREC-STM/2020-AS-37) Results: Increasing age, male sex and presence of co-morbidities (viz. Diabetes, COPD) are significantly associated with the occurrence of moderate and severe disease. Drugs (viz. ACEI/ARB), though are associated with less severe disease, have not achieved statistical significance, in the present study.
Conclusion:
Drugs, like ACEI/ARB, should be continued in patients suffering from COVID-19 infection, (if they are already on these drugs).
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
01:17Antihypertensive Drugs: Action of β1 Blockers
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...